Immune-checkpoint inhibition for metastatic triple-negative breast cancer: safety first?

被引：46

作者：

D'Abreo, Nina ^{[1
]}

Adams, Sylvia ^{[2
]}

机构：

[1] NYU, Winthrop Hosp, Oncol Hematol Div, Mineola, NY USA

[2] NYU, Langone Med Ctr, Laura & Isaac Perlmutter Canc Ctr, New York, NY 10003 USA

来源：

NATURE REVIEWS CLINICAL ONCOLOGY | 2019年 / 16卷 / 07期

关键词：

D O I：

10.1038/s41571-019-0216-2

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Breast oncologists are intimately familiar with managing treatment-related adverse events of endocrine, cytotoxic and targeted therapies, but the approval of immune-checkpoint inhibitors (ICIs) for metastatic triple-negative breast cancer (TNBC) poses new challenges. Herein, we discuss the safety of ICIs in metastatic TNBC, with an emphasis on immune-related adverse events.

引用

页码：399 / 400

页数：2

共 9 条

[1]

Adams S, 2019, ANN ONCOL, V30, P405, DOI [10.1093/annonc/mdy518, 10.1093/annonc/mdy517]

[2] Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up A Phase 1b Clinical Trial [J].

Adams, Sylvia ;

Diamond, Jennifer R. ;

Hamilton, Erika ;

Pohlmann, Paula R. ;

Tolaney, Sara M. ;

Chang, Ching-Wei ;

Zhang, Wei ;

Iizuka, Koho ;

Foster, Paul G. ;

Molinero, Luciana ;

Funke, Roel ;

Powderly, John .

JAMA ONCOLOGY, 2019, 5 (03) :334-342

[3] Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline [J].

Brahmer, Julie R. ;

Lacchetti, Christina ;

Schneider, Bryan J. ;

Atkins, Michael B. ;

Brassil, Kelly J. ;

Caterino, Jeffrey M. ;

Chau, Ian ;

Ernstoff, Marc S. ;

Gardner, Jennifer M. ;

Ginex, Pamela ;

Hallmeyer, Sigrun ;

Chakrabarty, Jennifer Holter ;

Leighl, Natasha B. ;

Mammen, Jennifer S. ;

McDermott, David F. ;

Naing, Aung ;

Nastoupil, Loretta J. ;

Phillips, Tanyanika ;

Porter, Laura D. ;

Puzanov, Igor ;

Reichner, Cristina A. ;

Santomasso, Bianca D. ;

Seigel, Carole ;

Spira, Alexander ;

Suarez-Almazor, Maria E. ;

Wang, Yinghong ;

Weber, Jeffrey S. ;

Wolchok, Jedd D. ;

Thompson, John A. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (17) :1714-+

[4] Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study [J].

Dirix, Luc Y. ;

Takacs, Istvan ;

Jerusalem, Guy ;

Nikolinakos, Petros ;

Arkenau, Hendrik-Tobias ;

Forero-Torres, Andres ;

Boccia, Ralph ;

Lippman, Marc E. ;

Somer, Robert ;

Smakal, Martin ;

Emens, Leisha A. ;

Hrinczenko, Borys ;

Edenfield, William ;

Gurtler, Jayne ;

von Heydebreck, Anja ;

Grote, Hans Juergen ;

Chin, Kevin ;

Hamilton, Erika P. .

BREAST CANCER RESEARCH AND TREATMENT, 2018, 167 (03) :671-686

[5] Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer A Phase 1 Study [J].

Emens, Leisha A. ;

Cruz, Cristina ;

Eder, Joseph Paul ;

Braiteh, Fadi ;

Chung, Cathie ;

Tolaney, Sara M. ;

Kuter, Irene ;

Nanda, Rita ;

Cassier, Philippe A. ;

Delord, Jean-Pierre ;

Gordon, Michael S. ;

ElGabry, Ehab ;

Chang, Ching-Wei ;

Sarkar, Indrani ;

Grossman, William ;

O'Hear, Carol ;

Fasso, Marcella ;

Molinero, Luciana ;

Schmid, Peter .

JAMA ONCOLOGY, 2019, 5 (01) :74-82

[6] Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): Results from I-SPY 2 [J].

Nanda, Rita ;

Liu, Minetta C. ;

Yau, Christina ;

Asare, Smita ;

Hylton, Nola ;

Van't Veer, Laura ;

Perlmutter, Jane ;

Wallace, Anne M. ;

Chien, Amy Jo ;

Forero-Torres, Andres ;

Ellis, Erin ;

Han, Heather ;

Clark, Amy Sanders ;

Albain, Kathy S. ;

Boughey, Judy Caroline ;

Elias, Anthony D. ;

Berry, Donald A. ;

Yee, Douglas ;

DeMichele, Angela ;

Esserman, Laura .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35

[7] Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study [J].

Nanda, Rita ;

Chow, Laura Q. M. ;

Dees, E. Claire ;

Berger, Raanan ;

Gupta, Shilpa ;

Geva, Ravit ;

Pusztai, Lajos ;

Pathiraja, Kumudu ;

Aktan, Gursel ;

Cheng, Jonathan D. ;

Karantza, Vassiliki ;

Buisseret, Laurence .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (21) :2460-+

[8]

Santa-Maria Cesar August, 2018, Oncotarget, V9, P18985, DOI 10.18632/oncotarget.24867

[9] Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer [J].

Schmid, P. ;

Adams, S. ;

Rugo, H. S. ;

Schneeweiss, A. ;

Barrios, C. H. ;

Iwata, H. ;

Dieras, V. ;

Hegg, R. ;

Im, S. -A. ;

Wright, G. Shaw ;

Henschel, V. ;

Molinero, L. ;

Chui, S. Y. ;

Funke, R. ;

Husain, A. ;

Winer, E. P. ;

Loi, S. ;

Emens, L. A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (22) :2108-2121

← 1 →